Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors

A single centre experience

A. Filice, A. Fraternali, A. Frasoldati, M. Asti, E. Grassi, L. Massi, M. Sollini, A. Froio, P. A. Erba, A. Versari

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The aim of this study was to assess the efficacy of PRRT in patients with advanced neuroendocrine tumors (NETs). Patients and Methods. From January 2007 to August 2011, we enrolled 65 patients (m/f 38/27; mean age 65 years, range 3383) with advanced NETs having enhanced SSTR expression, treated with PRRT. The enhanced expression of SSTR was assessed using 68Ga-DOTATOC/DOTATATE PET/CT. Among all the enrolled patients, 6 of them were excluded from the present analysis since they voluntarily interrupted treatment. Mean activity/cycle of 2.6 GBq ( 90Y-DOTATOC/DOTATATE) or 6.0 GBq ( 177Lu-DOTATOC/DOTATATE) was administrated intravenously (max 9 cycles). Results. Complete response (CR) was found in 1/59 (2%) patients, partial remission (PR) in 24/59 (40.5%) patients, stable disease (SD) in 24/59 (40.5%), and progression (PD) in 10/59 (17%) patients. The overall tumor response rate (CR + PR) was 42.5. In 40.5 of patients, the disease could be stabilized. Overall, 49 out of 59 patients had no tumor progression (83%). Twelve patients out of 59 (20%) had grade 2-3 hematological side effects including anemia, thrombocytopenia, and leukopenia. Long-term nephrotoxicity was observed in 3 patients (2 moderate, 1 severe). Conclusions. PRRT is a promising perspective for patients with advanced NETs.

Original languageEnglish
Article number320198
JournalJournal of Oncology
DOIs
Publication statusPublished - 2012

Fingerprint

Neuroendocrine Tumors
Somatostatin
Therapeutics
Activity Cycles
Leukopenia
Thrombocytopenia
Anemia
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

@article{1d0f2a09ac174f8ea0d423e82a810dfe,
title = "Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: A single centre experience",
abstract = "The aim of this study was to assess the efficacy of PRRT in patients with advanced neuroendocrine tumors (NETs). Patients and Methods. From January 2007 to August 2011, we enrolled 65 patients (m/f 38/27; mean age 65 years, range 3383) with advanced NETs having enhanced SSTR expression, treated with PRRT. The enhanced expression of SSTR was assessed using 68Ga-DOTATOC/DOTATATE PET/CT. Among all the enrolled patients, 6 of them were excluded from the present analysis since they voluntarily interrupted treatment. Mean activity/cycle of 2.6 GBq ( 90Y-DOTATOC/DOTATATE) or 6.0 GBq ( 177Lu-DOTATOC/DOTATATE) was administrated intravenously (max 9 cycles). Results. Complete response (CR) was found in 1/59 (2{\%}) patients, partial remission (PR) in 24/59 (40.5{\%}) patients, stable disease (SD) in 24/59 (40.5{\%}), and progression (PD) in 10/59 (17{\%}) patients. The overall tumor response rate (CR + PR) was 42.5. In 40.5 of patients, the disease could be stabilized. Overall, 49 out of 59 patients had no tumor progression (83{\%}). Twelve patients out of 59 (20{\%}) had grade 2-3 hematological side effects including anemia, thrombocytopenia, and leukopenia. Long-term nephrotoxicity was observed in 3 patients (2 moderate, 1 severe). Conclusions. PRRT is a promising perspective for patients with advanced NETs.",
author = "A. Filice and A. Fraternali and A. Frasoldati and M. Asti and E. Grassi and L. Massi and M. Sollini and A. Froio and Erba, {P. A.} and A. Versari",
year = "2012",
doi = "10.1155/2012/320198",
language = "English",
journal = "Journal of Oncology",
issn = "1687-8450",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors

T2 - A single centre experience

AU - Filice, A.

AU - Fraternali, A.

AU - Frasoldati, A.

AU - Asti, M.

AU - Grassi, E.

AU - Massi, L.

AU - Sollini, M.

AU - Froio, A.

AU - Erba, P. A.

AU - Versari, A.

PY - 2012

Y1 - 2012

N2 - The aim of this study was to assess the efficacy of PRRT in patients with advanced neuroendocrine tumors (NETs). Patients and Methods. From January 2007 to August 2011, we enrolled 65 patients (m/f 38/27; mean age 65 years, range 3383) with advanced NETs having enhanced SSTR expression, treated with PRRT. The enhanced expression of SSTR was assessed using 68Ga-DOTATOC/DOTATATE PET/CT. Among all the enrolled patients, 6 of them were excluded from the present analysis since they voluntarily interrupted treatment. Mean activity/cycle of 2.6 GBq ( 90Y-DOTATOC/DOTATATE) or 6.0 GBq ( 177Lu-DOTATOC/DOTATATE) was administrated intravenously (max 9 cycles). Results. Complete response (CR) was found in 1/59 (2%) patients, partial remission (PR) in 24/59 (40.5%) patients, stable disease (SD) in 24/59 (40.5%), and progression (PD) in 10/59 (17%) patients. The overall tumor response rate (CR + PR) was 42.5. In 40.5 of patients, the disease could be stabilized. Overall, 49 out of 59 patients had no tumor progression (83%). Twelve patients out of 59 (20%) had grade 2-3 hematological side effects including anemia, thrombocytopenia, and leukopenia. Long-term nephrotoxicity was observed in 3 patients (2 moderate, 1 severe). Conclusions. PRRT is a promising perspective for patients with advanced NETs.

AB - The aim of this study was to assess the efficacy of PRRT in patients with advanced neuroendocrine tumors (NETs). Patients and Methods. From January 2007 to August 2011, we enrolled 65 patients (m/f 38/27; mean age 65 years, range 3383) with advanced NETs having enhanced SSTR expression, treated with PRRT. The enhanced expression of SSTR was assessed using 68Ga-DOTATOC/DOTATATE PET/CT. Among all the enrolled patients, 6 of them were excluded from the present analysis since they voluntarily interrupted treatment. Mean activity/cycle of 2.6 GBq ( 90Y-DOTATOC/DOTATATE) or 6.0 GBq ( 177Lu-DOTATOC/DOTATATE) was administrated intravenously (max 9 cycles). Results. Complete response (CR) was found in 1/59 (2%) patients, partial remission (PR) in 24/59 (40.5%) patients, stable disease (SD) in 24/59 (40.5%), and progression (PD) in 10/59 (17%) patients. The overall tumor response rate (CR + PR) was 42.5. In 40.5 of patients, the disease could be stabilized. Overall, 49 out of 59 patients had no tumor progression (83%). Twelve patients out of 59 (20%) had grade 2-3 hematological side effects including anemia, thrombocytopenia, and leukopenia. Long-term nephrotoxicity was observed in 3 patients (2 moderate, 1 severe). Conclusions. PRRT is a promising perspective for patients with advanced NETs.

UR - http://www.scopus.com/inward/record.url?scp=84866239458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866239458&partnerID=8YFLogxK

U2 - 10.1155/2012/320198

DO - 10.1155/2012/320198

M3 - Article

JO - Journal of Oncology

JF - Journal of Oncology

SN - 1687-8450

M1 - 320198

ER -